Rekha Jhunjhunwala, the wife of Rakesh Jhunjhunwala, has raised stake in Jubilant Pharmova Ltd, showed shareholding for the period ended September 30, 2021, on the BSE. Jubilant Therapeutics is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.   

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

As per the September shareholding figures available at Trendlyne, Rekha Jhunjhunwala now has 3.2 per cent stake in the company. She holds 5,020,000 shares of the pharma company worth Rs 319.6 crore as on October 20, 2021, showed Trendlyne, a platform for stock market analysis    

At 10.20 am, Jubilant Pharmova Ltd shares were trading flat at Rs 634.95, up Rs 4.05 or 0.64% in the intraday trade on BSE. The stock has hit a 52-week high of Rs 981.90 February 8, 2021 and a year low of Rs 584.95 on, August 24, 2021.    

See Zee Business Live TV Streaming Below:

Earlier, Rakesh Jhunjhunwala, the big bull of the Indian stock market, has cut his position in Tarc Ltd and Multi Commodity Exchange of India Ltd, showed BSE data on Tuesday. The Indian billionaire now only has 4,695,000 stocks worth Rs 20 crore Tarc Limited, while he now has below 1 per cent stake in MCX against 4.9% stake in June quarter,  showed Trendlyne data on October 19, 2021.   

Tarc Ltd is also the stock which saw celebrity investor Ashish Kacholia increasing his stake to over 1 per cent. Kacholia held 1.5% stake comprising 4,425,000 equity shares worth Rs 18.8 crore in Tarc Ltd as on October 19, 2021, as per the same platform.    

Meanwhile, Jubilant Pharmova Ltd will hold the Company's Board meeting on October 22 to consider results of the company for the quarter ended September 30, 2021. " We wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 22, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2021," said company in a BSE filing.   

Jubilant Pharma Limited is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 Radiopharmacies in the US.  currently operate four US FDA approved manufacturing facilities in North America and two US FDA approved manufacturing facilities in India.